ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Anika Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$20.22+0.24 (+1.20%)
Close on Oct 19, 2026
- Market cap
- $277.36M
- P/E (TTM)
- –
- Dividend yield
- –
Anika Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OEM Channel [Member] | $64.41M | $77.77M | $84.65M | $81.68M | – | – | – | – | – | – | 57.1% | -17.2% |
| Commercial Channel [Member] | $48.41M | $42.14M | $36.15M | $32.15M | – | – | – | – | – | – | 42.9% | +14.9% |
| Dermal [Member] | – | – | – | – | – | – | $2.24M | $396.00K | $2.76M | $2.76M | – | – |
| Orthobiologics [Member] | – | – | – | – | – | – | $101.00M | $93.56M | $93.82M | $89.70M | – | – |
| Surgical [Member] | – | – | – | – | – | – | $5.18M | $5.51M | $5.26M | $5.43M | – | – |
| Other [Member] | – | – | – | – | – | – | – | – | $5.95M | $5.05M | – | – |
| Product [Member] | – | – | – | – | $147.79M | $130.46M | $114.51M | $105.53M | $107.78M | $102.93M | – | – |
| Service [Member] | – | – | – | – | – | $0 | $98.00K | $24.00K | $5.64M | $447.00K | – | – |
| Manufactured Product, Other [Member] | – | – | – | – | – | $8.06M | $8.98M | $7.69M | $5.95M | $5.05M | – | – |
| Joint Pain Management Therapies [Member] | – | – | – | – | – | $83.03M | $103.47M | $96.72M | – | – | – | – |
| Joint Preservation and Restoration [Member] | – | – | $54.88M | $50.40M | $48.59M | $39.37M | $2.07M | $1.13M | – | – | – | – |
| Non-Orthopedic [Member] | – | – | $9.86M | $13.85M | $14.12M | $8.06M | $8.98M | – | – | – | – | – |
| OA Pain Management [member] | – | – | $101.93M | $91.98M | $85.08M | $83.03M | $103.47M | – | – | – | – | – |
| Licensing, Milestone and Contract Revenue [Member] | – | – | – | – | $0 | $0 | $98.00K | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $70.06M | $82.45M | $86.91M | $83.75M | $113.83M | $103.18M | $90.30M | $85.35M | $92.91M | $83.97M | 62.1% | -15.0% |
| Europe [Member] | $22.21M | $19.40M | $17.31M | $17.23M | $19.58M | $14.18M | $14.74M | $11.73M | $12.44M | $10.95M | 19.7% | +14.5% |
| Other Location [Member] | $20.55M | $18.06M | $16.57M | $12.85M | $14.38M | $13.10M | $9.56M | $8.47M | $8.08M | $8.45M | 18.2% | +13.8% |
From the segment and revenue-disaggregation notes of Anika Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.